早期清醒俯卧位在中轻度急性呼吸窘迫综合征患者中的应用效果及影响因素
该前瞻性队列研究纳入2020年1月至2023年6月颍上县人民医院急诊科收治的107例中轻度ARDS患者,按俯卧位耐受试验分为清醒俯卧位组61例与非俯卧位组46例,均按标准流程给予HFNC,俯卧位组入院12小时内开始俯卧位、每天至少1次、每次至少2小时。结果显示俯卧位组24小时PaO2/FiO2较0小时显著升高,48、72小时PaO2/FiO2显著高于非俯卧位组,NIV使用率、ICU转入率更低,HFNC时间、NIV时间及总住院时间更短。61例俯卧位患者中39例成功、22例失败,高BMI和非无症状性低氧血症是失败的危险因素,较高PaO2/FiO2、俯卧位2小时ROX指数及延长每日俯卧位时间为保护因素。
要点
- 俯卧位组入院24小时PaO2/FiO2即较0小时显著升高(191.94±17.86 vs. 179.24±29.27 mmHg,P<0.05),非俯卧位组仅72小时差异有统计学意义。
- 俯卧位组NIV使用率36.1%(22/61)显著低于非俯卧位组56.5%(26/46),P<0.05,Kaplan-Meier分析示NIV累积使用率更低(χ²=5.402,P=0.020)。
- 俯卧位组ICU转入率11.5%(7/61)显著低于非俯卧位组28.3%(13/46),P<0.05,HFNC时间、NIV时间及总住院时间均显著缩短。
- 俯卧位失败组BMI更高(26.61±4.70 vs. 22.91±5.50 kg/m²)、PaO2/FiO2更低(163.73±24.73 vs. 185.69±28.87 mmHg)、每日俯卧位时间更短(5.87±2.85 vs. 8.05±1.99小时),均P<0.05。
- 多因素Logistic回归:BMI(OR=1.447,95%CI 1.105-2.063)和非无症状性低氧血症(OR=13.274,95%CI 1.548-117.390)为失败危险因素;PaO2/FiO2(OR=0.831,95%CI 0.770-0.907)、每日俯卧位时间(OR=0.482,95%CI 0.236-0.924)、俯卧位2小时ROX指数(OR=0.381,95%CI 0.169
适用人群与场景
- 2020年1月至2023年6月颍上县人民医院急诊科收治的中轻度急性呼吸窘迫综合征(ARDS)患者。
- 按俯卧位耐受试验结果分为清醒俯卧位组(61例)和非俯卧位组(46例),全部按标准流程接受经鼻高流量氧疗(HFNC)。
诊断标准与关键阈值
- 俯卧位耐受试验:原文未给出具体试验方法与判定阈值;患者据此分为清醒俯卧位组与非俯卧位组。
- 俯卧位成功定义为成功终止HFNC;俯卧位失败定义为转为无创通气(NIV)或转入ICU。
处置流程与药物剂量
- 所有患者按标准流程给予HFNC。
- 清醒俯卧位组在标准治疗基础上于入院12小时内开始俯卧位治疗,可分多次进行、每天至少1次、每次至少2小时。
- 为尽可能延长俯卧位时间,允许患者活动或保持小角度侧俯卧位。
红旗征与不能漏的情况
- 非无症状性低氧血症是俯卧位失败的危险因素(OR=13.274,95%CI 1.548-117.390)。
- 高BMI是俯卧位失败的危险因素(OR=1.447,95%CI 1.105-2.063)。
研究设计与关键结果
- 前瞻性队列研究,最终纳入107例中轻度ARDS患者,清醒俯卧位组61例、非俯卧位组46例;两组PaO2/FiO2均随入院时间延长逐渐升高。
- 俯卧位组入院24小时PaO2/FiO2较0小时显著升高(mmHg:191.94±17.86 vs. 179.24±29.27,P<0.05);非俯卧位组仅72小时差异有统计学意义(mmHg:198.24±17.99 vs. 181.24±16.62,P<0.05)。
- 俯卧位组入院48小时和72小时PaO2/FiO2显著高于非俯卧位组。
- 俯卧位组NIV使用率显著低于非俯卧位组[36.1%(22/61)vs. 56.5%(26/46),P<0.05];Kaplan-Meier曲线分析证实俯卧位组使用NIV更晚,NIV累积使用率显著低于非俯卧位组(Log-Rank检验:χ²=5.402,P=0.020)。
- 俯卧位组ICU转入率显著低于非俯卧位组[11.5%(7/61)vs. 28.3%(13/46),P<0.05]。
- 俯卧位组HFNC时间、NIV时间及总住院时间均显著短于非俯卧位组[HFNC时间(天):5.71±1.45 vs. 7.24±3.36,NIV时间(天):3.27±1.28 vs. 4.40±1.47,总住院时间(天):11(7,13)vs. 14(10,19),均P<0.05]。
- 61例俯卧位患者中39例成功、22例失败;失败组较成功组BMI更高[BMI(kg/m²):26.61±4.70 vs. 22.91±5.50]、PaO2/FiO2更低[(mmHg):163.73±24.73 vs. 185.69±28.87]、无症状性低氧血症比例更低[18.2%(4/22)vs. 46.2%(18/39)]、俯卧位2小时ROX指数更低(5.75±1.18 vs. 7.21±1.45)、每日俯卧位时间更短[(小时):5.87±2.85 vs. 8.05±1.99],均P<0.05。
- 二元多因素Logistic回归分析显示上述因素均为清醒俯卧位结局的影响因素(均P<0.05):BMI(OR=1.447,95%CI 1.105-2.063)和非无症状性低氧血症(OR=13.274,95%CI 1.548-117.390)为失败危险因素;PaO2/FiO2(OR=0.831,95%CI 0.770-0.907)、每日俯卧位时间(OR=0.482,95%CI 0.236-0.924)、俯卧位2小时ROX指数(OR=0.381,95%CI 0.169-0.861)为保护因素。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对HFNC支持的中轻度ARDS患者,入院12小时内启动清醒俯卧位(每天至少1次、每次至少2小时,允许小角度侧俯卧位以延长俯卧位时间)可降低NIV使用率与ICU转入率并缩短住院时间。
- 高BMI患者俯卧位失败风险升高(OR=1.447),非无症状性低氧血症患者失败风险更高(OR=13.274),应关注此类人群的俯卧位结局。
- 俯卧位2小时ROX指数较高、PaO2/FiO2较高及每日俯卧位时间较长与俯卧位成功相关,可在床旁用于评估俯卧位反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the application effect of early awake prone position in mild-to-moderate acute respiratory distress syndrome (ARDS) patients, and analyze the related factors affecting the prone position outcome.
METHODS: A prospective cohort study was conducted. The mild-to-moderate ARDS patients admitted to the emergency department of Yingshang County People's Hospital from January 2020 to June 2023 were enrolled as the research subjects. According to the results of prone tolerance test, the patients were divided into awake prone position group and non-prone position group. All patients were given high flow nasal cannula (HFNC) according to the standard procedures. The patients in the awake prone position group received prone position treatment within 12 hours after admission, in addition to the standard treatment. This could be performed in several times, at least once a day, and at least 2 hours each time. In order to prolong the prone position as much as possible, the patients were allowed to move or keep a small angle side prone. The changes of oxygenation index (PaO2/FiO2) at 0, 24, 48, and 72 hours after admission, the rate of intensive care unit (ICU) transfer, the use rate and use time of non-invasive ventilation (NIV), the total hospital stay, and the daily prone position time and 2-hour ROX index [ratio of pulse oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) and respiratory rate (RR)] of prone position patients were recorded. The successful termination of HFNC was defined as the successful prone position, and the failure of prone position was defined as switching to NIV or transferring to ICU. Subgroup analysis was performed, and the binary multivariate Logistic regression analysis was used to screen the influencing factors of the early awake prone position outcome.
RESULTS: A total of 107 patients were finally enrolled, with 61 in the awake prone position group and 46 in the non-prone position group. Both groups showed a gradual increase in PaO2/FiO2 with prolonged admission time. The PaO2/FiO2 at 24 hours after admission in the awake prone position group was significantly higher than that at 0 hour [mmHg (1 mmHg ≈ 0.133 kPa): 191.94±17.86 vs. 179.24±29.27, P < 0.05], while the difference in the non-prone position group was only statistically significant at 72 hours (mmHg: 198.24±17.99 vs. 181.24±16.62, P < 0.05). Furthermore, the PaO2/FiO2 at 48 hours and 72 hours after admission in the awake prone position group was significantly higher than that in the non-prone position group. The use rate of NIV in the awake prone position group was significantly lower than that in the non-prone position group [36.1% (22/61) vs. 56.5% (26/46), P < 0.05]; Kaplan-Meier curve analysis further confirmed that the patients in the awake prone position group used NIV later, and the cumulative rate of NIV usage was significantly lower than that in the non-prone position group (Log-Rank test: χ 2 = 5.402, P = 0.020). Compared with the non-prone position group, the ICU transfer rate in the awake prone position group was significantly lowered [11.5% (7/61) vs. 28.3% (13/46), P < 0.05], and the HFNC time, NIV time, and total hospital stay were significantly shortened [HFNC time (days): 5.71±1.45 vs. 7.24±3.36, NIV time (days): 3.27±1.28 vs. 4.40±1.47, total hospital stay (days): 11 (7, 13) vs. 14 (10, 19), all P < 0.05]. Of the 61 patients who underwent awake prone positioning, 39 were successful, and 22 failed. Compared with the successful group, the patients in the failure group had a higher body mass index [BMI (kg/m2): 26.61±4.70 vs. 22.91±5.50, P < 0.05], lower PaO2/FiO2, proportion of asymptomatic hypoxemia and 2-hour ROX index of prone position [PaO2/FiO2 (mmHg): 163.73±24.73 vs. 185.69±28.87, asymptomatic hypoxemia proportion: 18.2% (4/22) vs. 46.2% (18/39), 2-hour ROX index of prone position: 5.75±1.18 vs. 7.21±1.45, all P < 0.05], and shorter daily prone positioning time (hours: 5.87±2.85 vs. 8.05±1.99, P < 0.05). Binary multivariate Logistic regression analysis showed that all these factors were influencing factors for the outcome of awake prone positioning (all P < 0.05), among which BMI [odds ratio (OR) = 1.447, 95% confidence interval (95%CI) was 1.105-2.063] and non-asymptomatic hypoxemia (OR = 13.274, 95%CI was 1.548-117.390) were risk factors for failure of prone position, while PaO2/FiO2 (OR = 0.831, 95%CI was 0.770-0.907), daily prone positioning time (OR = 0.482, 95%CI was 0.236-0.924), and 2-hour ROX index of prone position (OR = 0.381, 95%CI was 0.169-0.861) were protective factors.
CONCLUSIONS: Early awake prone positioning in patients with mild-to-moderate ARDS supported by HFNC is safe and feasible, reducing the use rate and duration of NIV, lowering the ICU transfer rate, and shortening the hospital stay. High BMI and non-asymptomatic hypoxemia are risk factors for failed prone position, while higher PaO2/FiO2 and the ROX index within 2 hours of prone position (the patient's good response to prone position), and prolonged daily prone position can improve the success rate of prone position.
参考来源
- Lei Z, Liu L, Wang X, et al. [Application effect and influencing factors of early awake prone position in patients with mild-to-moderate acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39223883. doi:10.3760/cma.j.cn121430-20230925-00817
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。